Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $428.77M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.76M
Average 0.51M
PRTA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Prothena Corporation plcNASDAQ: PRTA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $6.92M fell 36.8% year over year, behind the -24.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at +6.3% a year.
Context
- Stock-based compensation amounted to 388.7% of revenue in FY2025, up 354.7 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -36.8% toward the trailing-twelve-month pace of -24.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 37.64M USD
- Year-over-year change
- -18.1%
- 4-year CAGR
- +11.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.64M | -18.1% |
| FY2024 | 2024-12-31 | 45.96M | +12.3% |
| FY2023 | 2023-12-31 | 40.91M | +30.6% |
| FY2022 | 2022-12-31 | 31.32M | +27.0% |
| FY2021 | 2021-12-31 | 24.66M | — |
Stock-Based Compensation vs competitors
How PRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -24.5% is the 6th highest of 10, against a peer median of -21.9%.
- Stock-based compensation amounts to 58.0% of revenue for PRTA, versus a peer median of 75.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $857.38M USD | +71257.3% | +9.4% | — | |
| LTM Jun 2026 | $134.9M USD | -55.6% | +4.6% | 1.4% | |
| LTM Jun 2026 | $69.95M USD | +39.2% | -0.1% | 1941.0% | |
| LTM Mar 2026 | $33.61M USD | -24.5% | +6.3% | 58.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M USD | -33.3% | +53.3% | — |
| LTM Mar 2026 | $15.5M USD | -21.9% | -3.9% | — | |
| LTM Dec 2025 | $10.6M USD | +15.1% | -14.3% | — | |
| LTM Mar 2026 | $9.77M USD | +1.5% | +47.6% | — | |
| LTM Dec 2025 | CHF 2.68M CHF | -42.8% | — | 75.0% | |
| LTM Mar 2026 | $1.83M USD | -42.1% | -16.4% | — | |
| Peer median (excluding PRTA) | — | -21.9% | +2.3% | 75.0% | |
Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 66.98M | (116.95M) | (147.03M) | (122.31M) | (244.09M) |
| Depreciation & Amortization | 1.12M | 744K | 928K | 893K | 895K |
| Deferred Income Tax | 4.57M | (11.13M) | (15.69M) | (9.35M) | 43.24M |
| Stock-Based Compensation | 24.66M | 31.32M | 40.91M | 45.96M | 37.64M |
| Change in Working Capital | (10.4M) | (18.8M) | (20.53M) | (67.94M) | (4.17M) |
| Accounts Receivables | 15K | 0 | (5.16M) | 5.16M | 0 |
| Inventory | 0 | 0 | (8.9M) | 0 | 0 |
| Accounts Payables | (492K) | 11.87M | 22.86M | (18.3M) | (15.78M) |
| Other Working Capital | (9.93M) | (30.67M) | (29.33M) | (54.8M) | 11.6M |
| Other Non-Cash Items | 5.69M | 6M | 7.5M | 2.69M | 2.91M |
| Operating Cash Flow | 92.61M | (108.82M) | (133.91M) | (150.05M) | (163.58M) |
| Capital Expenditures | (575K) | (464K) | (2.81M) | (298K) | (138K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 37K | 0 | 0 |
| Investing Cash Flow | (575K) | (464K) | (2.77M) | (298K) | (138K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 174.79M | 223.62M | 23.58M | 0 | (139K) |
| Common Stock Repurchased | 0 | 0 | 0 | (353K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.54M | 17.84M | 21.52M | 1.91M | 0 |
| Financing Cash Flow | 190.33M | 241.46M | 45.1M | 1.55M | (139K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 282.36M | 132.17M | (91.58M) | (148.79M) | (163.86M) |
| Free Cash Flow | 92.03M | (109.29M) | (136.72M) | (150.35M) | (163.72M) |
Prothena Corporation plc
NASDAQ:PRTA
Intrinsic Alpha fair value
Locked
Current Price
$8.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.